People · Operator
Named in public records as an officer, director or promoter · active 2020–2020 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Evolus, Inc. | — | Pharmaceuticals | Series B | $40.5M | $1.4B | 2020 |
Michael Jafar at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Jafar on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Gill | 1 | 8 |
| Vikram Malik | 1 | 5 |
| Simone Blank | 1 | 5 |
| Peter Farrell | 1 | 4 |
| Lauren Silvernail | 1 | 2 |
| Robert Hayman | 1 | 2 |
| John Christopher Gross | 1 | 1 |
| Scott Christopher Cannizzaro | 1 | 1 |
| J. Christopher Marmo | 1 | 1 |
| Rui Avelar | 1 | 1 |
| Karah Parschauer | 1 | 1 |
| David Moatazedi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.